Many individual investors have opted to invest in biotech ETFs and mutual funds. The XBI and SBIO funds have performed well because they focus more on small and mid-sized biotech companies. The IBB, which has emerged as something of a proxy for the industry for many investors, is weighted much more heavily to bigger, more proven biotech companies.The volatility of […]
With many investors starting to get more scared about China, scared about Europe and even scared about the coming interest rate hike cycle from the Federal Reserve, some smart money investors may be trying to figure out which stocks have already been heavily discounted to factor in bad news already. It may be impossible to ever know if a true […]
By Ben LevisohnInvestors love biotech stocks, but heading into July, Amgen (AMGN) was unloved, especially compared to its other biotech giants like Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD) and Biogen (BIIB). No longer. Shares of Amgen have jumped nearly 6% after reporting better than forecast earnings and raising its guidance. UBS analyst Matthew Roden has the details:
Amgen reported another strong […]
Several major biotech companies like Biogen (BIIB – Analyst Report), AbbVie (ABBV – Analyst Report), Celgene and Gilead reported second quarter results over the last five trading days. Biogen has been grabbing headlines for the wrong reasons – although the company’s earnings were better-than-expected, revenues missed expectations.With the company saying that it is cutting its outlook based on revised expectations […]
By Steve SearsGoldman Sachs is telling clients to hedge the bio-technology sector in anticipation of a sharp decline. Early Monday, the bank told clients to buy SPDR S&P Biotech ETF (XBI) December $230 puts. During the pre-market, the ETF was priced at $255, and the put was at $15.50.
SSPL via Getty Images
“These puts are about 10% out-of-the-money and cost about […]
NEW YORK The S&P 500 and Nasdaq posted their largest weekly drops since March on Friday as slowing global growth dragged commodity-related stocks lower, while an earnings-related drop in Biogen took down the biotech sector.The Dow Jones industrial average .DJI fell 162.19 points, or 0.91 percent, to 17,569.73, the S&P 500 .SPX lost 22.33 points, or 1.06 percent, to 2,079.82 […]
Martin Ritchie and Agnieszka De Sousa of Bloomberg report, Copper Poised for Worst Week Since January as Commodities Slump:
Copper traded near the lowest since 2009 as Chinese manufacturing data added to evidence that demand is slowing in the world’s biggest user of raw materials.The preliminary Purchasing Managers’ Index from Caixin Media and Markit Economics unexpectedly fell to the lowest in […]
While the stocks are not cheap, they’re not expensive, he added. What investors are paying for is high quality growth and high quality earnings.Read MoreCramer: Secret pattern to unlocking biotech richesIn fact, he thinks people have underappreciated biotech’s “fantastic” margins, noting that the companies now have 50 to 70 percent operating margins and “tons of real cash flow.””These are real […]
The growth is just getting started at Biogen Idec (NASDAQ: BIIB ) . OK, so it’s been ongoing for quite some time, but it certainly isn’t about to end anytime soon. The company recently launched Tecfidera for multiple sclerosis in the United States, completed three regulatory filings, is expecting three market launches in 2014, and has major trials releasing data […]
By Ben LevisohnIt’s been a bad, bad week for biotech stocks. The iShares Nasdaq Biotech Index ETF (IBB) had dropped 9.3% this week through Thursday’s close, while Amgen (AMGN), Biogen Idec (BIIB), and Celgene (CELG) also suffered big losses. Evercore ISI’s Mark Schoenebaum notes that the valuations of big biotech companies is trading below that of the S&P 500 for only the […]
